Cannabis Advertising Restrictions in Portugal

The legal framework in one page

Portugal's cannabis landscape sits across three separate laws, and advertising rules follow whichever one applies to the product.

• Recreational cannabis is a controlled substance under Decree-Law 15/93 ^[1]. Sale and trafficking are criminal offences. Personal possession of small quantities was decriminalised (not legalised) by Law 30/2000 ^[2] — it becomes an administrative matter, not a green light for commerce or promotion.
• Medical cannabis was authorised by Law 33/2018 of 18 July 2018 and implemented by Decree-Law 8/2019 ^[3][4]. Products, cultivation, and dispensing are supervised by Infarmed (Autoridade Nacional do Medicamento e Produtos de Saúde).
• General advertising rules live in the Código da Publicidade (Decree-Law 330/90) ^[5], while medicines-specific rules are in Decree-Law 176/2006, the Estatuto do Medicamento ^[6].

Because medical cannabis preparations are dispensed only by prescription, they are captured by the prescription-medicine advertising regime — which is where the restrictions bite. Strong evidence

What you cannot advertise to the public

Article 150 of Decree-Law 176/2006 prohibits advertising of prescription-only medicines to the general public ^[6]. Infarmed's guidance confirms this covers cannabis-based medicines and preparations authorised under Law 33/2018 ^[4][7].

In practice that means:

• No consumer-facing ads on TV, radio, print, outdoor, or digital.
• No influencer or social-media promotion of specific medical cannabis brands or products.
• No sponsored content, giveaways, discount codes, or affiliate schemes targeting consumers.
• No health claims ("treats anxiety," "helps sleep") in any consumer channel.

For recreational cannabis, advertising is not merely restricted — the underlying activity (sale) is criminal, so any advertising would also implicate Article 8 of the Advertising Code, which forbids promoting illegal goods or services ^[5]. Strong evidence

Coffeeshop-style marketing, cannabis-club promotion, and "grow shop" ads that cross into promoting personal cultivation for consumption sit in a legally exposed grey zone. Enforcement has been inconsistent Weak / limited, but the statutory position is clear.

What is allowed — narrowly

Advertising to healthcare professionals. Under Articles 153–157 of Decree-Law 176/2006, promotion of prescription medicines to doctors, pharmacists, and other prescribers is permitted if it is truthful, evidence-based, references the approved product information, and is not disguised as consumer content ^[6]. Infarmed can inspect materials and sanction breaches.

Institutional and scientific communication. Companies may publish scientific data, participate in medical congresses, and respond to unsolicited requests for information. General corporate communications that do not promote a specific product to consumers are typically outside the advertising ban.

Non-medicinal hemp and CBD products are treated separately. Cosmetics containing cannabidiol can be marketed if they comply with EU Regulation 1223/2009 and make no medicinal claims. CBD foods and supplements remain restricted under the EU Novel Food framework ^[8]; the European Commission classifies most CBD extracts as novel foods requiring pre-market authorisation, and Portuguese authorities follow that line Strong evidence. Making any therapeutic claim about a CBD product flips it back under medicines law.

Enforcement and penalties

Three regulators can act:

• Infarmed handles medicines-advertising breaches under Decree-Law 176/2006. Fines for illegal promotion of prescription medicines range into the tens of thousands of euros for companies, plus product-withdrawal orders ^[6].
• DGC (Direção-Geral do Consumidor) and ASAE enforce the general Advertising Code ^[5].
• ERC (Entidade Reguladora para a Comunicação Social) oversees broadcast and media compliance.

Criminal penalties under Decree-Law 15/93 apply where advertising promotes trafficking or illicit sale ^[1]. Publicly available Infarmed sanction decisions from recent years show active enforcement against unauthorised medicine promotion generally, though published cases specifically naming cannabis products are limited Weak / limited.

Recent and pending changes

• 2018–2019: Law 33/2018 and Decree-Law 8/2019 created the medical cannabis regime and, by extension, applied prescription-medicine advertising rules to cannabis preparations ^[3][4].
• 2021–2023: Infarmed authorised several cannabis-based preparations for the Portuguese market; none may be advertised to consumers ^[7].
• Recreational legalisation: As of the last verification date, no bill legalising recreational cannabis has been enacted. Proposals have been debated (notably from Bloco de Esquerda and Iniciativa Liberal) but not passed ^[9]. If any such law is enacted, expect it to include an advertising regime modelled on tobacco and alcohol restrictions rather than a permissive one [evidence:none — speculative].

Last verified: 15 June 2024. Check Infarmed and the Diário da República for updates before relying on this article.

Practical checklist

If you are a company operating in or into Portugal:

1. Classify the product: medicine, cosmetic, food/supplement, or industrial hemp. The advertising rules follow the classification.
2. If it is a medicine — assume no consumer advertising. Direct HCP materials must be pre-cleared internally against Infarmed guidance.
3. Avoid therapeutic claims on any non-medicinal cannabis or CBD product. A single "relieves pain" line can reclassify the product.
4. For influencer and social content, remember Portuguese law applies to ads targeted at Portuguese consumers regardless of where the platform or creator is based.
5. Keep records. Infarmed and DGC can request substantiation.

---

This is not legal advice. Cannabis and advertising law in Portugal is technical and enforcement-sensitive. Consult a Portuguese lawyer with regulatory experience before publishing anything.

Sources

How this page was made